Cho, Eun Kyung
4 papers on CoChat
Most cited papers
- Verified
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine
Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research
Cited by 5,508
- Verified
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Paz-Ares, L., Dvorkin, M., Chen, Y., Reinmuth, N., Hotta, K., Trukhin, D., Statsenko, G., Hochmair, M. J., Özgüroğlu, M., Ji, J. H., et al. (2019) · The Lancet
Lung Cancer Research StudiesCancer Immunotherapy and Biomarkers
Cited by 2,298
- Verified
CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Reungwetwattana, T., Nakagawa, K., Cho, B. C., Cobo, M., Cho, E. K., Bertolini, A., Bohnet, S., Zhou, C., Lee, K. H., Nogami, N., et al. (2018) · Journal of Clinical Oncology
Lung Cancer Treatments and MutationsBrain Metastases and Treatment
Cited by 811
- Verified
An open-label, randomized, parallel, phase III trial evaluating the efficacy and safety of polymeric micelle-formulated paclitaxel compared to conventional cremophor EL-based paclitaxel for recurrent or metastatic HER2-negative breast cancer
Park, I. H., Sohn, J. H., Kim, S. B., Lee, K. S., Chung, J. S., Lee, S. H., Kim, T. Y., Jung, K. H., Cho, E. K., Kim, Y. S., et al. (2017) · Cancer Research and Treatment
Cancer Treatment and PharmacologyNanoparticle-Based Drug Delivery
Cited by 133
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free